Dose-Dependent Effect of Platinum-Based Chemotherapy on the Risk of Metachronous Contralateral Testicular Cancer Osimertinib is a third-generation, CNS-active, irreversible, oral epidermal growth ...

Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy significantly improves OS compared to osimertinib monotherapy in patients ...

Trastuzumab Plus Gemcitabine-Cisplatin for Treatment-Naïve Human Epidermal Growth Factor Receptor 2–Positive Biliary Tract Adenocarcinoma: A Multicenter, Open-Label, Phase II Study (TAB) Patients were ...

Osimertinib improves progression-free survival compared to standard first line therapy in Asian patients with EGFR-mutated non-small-cell lung cancer (NSCLC), according to the Asian subset analysis of ...

The combination of osimertinib (Tagrisso, AstraZenca) plus chemotherapy is associated with continued benefits in previously untreated advanced EGFR-mutated non–small-cell lung cancer (NSCLC) even ...

Osimertinib plus chemotherapy showed a statistically significant improvement in progression-free survival (PFS) vs osimertinib alone in patients with epidermal growth factor receptor–mutated (EGFRm) ...

In this study, an UPLC-MS/MS method with specificity and accuracy was established to simultaneously quantify aumolertinib, osimertinib, gefitinib and their major metabolites (left). By using this ...

Besides the new approval, AstraZeneca released preliminary results for LAURA evaluating osimertinib after chemoradiotherapy. Of note, a prespecified exploratory analysis from FLAURA2 of patients with ...

Adding a mutation-specific targeted drug to osimertinib (Tagrisso) substantially increased the objective response rate (ORR) in newly diagnosed EGFR-mutant, MET-aberrant non-small cell lung cancer ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) Final overall survival (OS) results from the Phase III FLAURA2 trial demonstrate that first-line osimertinib plus chemotherapy ...